Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1

Swiss HIV Cohort Study; Frédérique Chammartin; Alexandra Griessbach; Katharina Kusejko; Annette Audigé; Selina Epp; Marcel P Stoeckle; Anna L Eichenberger; Alain Amstutz; Christof M Schoenenberger; Barbara Hasse; Dominique L Braun; Andri Rauch; Alexandra Trkola; Matthias Briel; Heiner C Bucher; Huldrych F Günthard; Benjamin Speich; Irene A Abela

doi:10.1097/QAD.0000000000003751

Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1

Swiss HIV Cohort Study
, Frédérique Chammartin
, Alexandra Griessbach
, Katharina Kusejko
, Annette Audigé
, Selina Epp
, Marcel P Stoeckle
, Anna L Eichenberger
, Alain Amstutz
, Christof M Schoenenberger
, Barbara Hasse
, Dominique L Braun
, Andri Rauch
, Alexandra Trkola
, Matthias Briel
, Heiner C Bucher
, Huldrych F Günthard
, Benjamin Speich
, Irene A Abela

Bristol Medical School (PHS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

6 Citations (Scopus)

Abstract

OBJECTIVES: This study aimed to investigate the association of demographic and clinical characteristics, including HIV-specific parameters with the antibody response to a third dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine in people with HIV-1 (PWH).

DESIGN: Post hoc analysis of data collected during the observational extension of the COrona VaccinE tRiAL pLatform trial (COVERALL-2) nested into the Swiss HIV Cohort Study (SHCS).

METHODS: Serological measurements were conducted on a total of 439 PWH who had received a third dose of either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. Antibody reactivity was assessed using the multifactorial ABCORA immunoassay that defines SARS-CoV-2 seroconversion and predicts neutralization activity. The association between log transformed antibody reactivity and various baseline factors, including vaccine type, demographics, immune and viral status, smoking status, comorbidities, infection history, and co-medication with chemotherapy and immunosuppressive drugs, was investigated using a multivariable linear regression model.

RESULTS: Antibody response to third SARS-CoV-2 vaccination was significantly lower among PWH with CD4 + cell count less than 350 cells/μl [ratio of means 0.79; 95% confidence interval (CI) 0.65-0.95]. Having a detectable HIV-1 viral load at least 50 copies/ml and being on concurrent chemotherapy was associated with an overall lower humoral immune response (ratio of means 0.75; 95% CI 0.57-1.00 and 0.34; 95% CI 0.22-0.52, respectively).

CONCLUSION: The study highlights the importance of optimal antiretroviral treatment for PWH, emphasizing the need for timely intervention to enhance the vaccine immunogenicity in this population. Moreover, it underscores the significance of sequential mRNA vaccination and provides important evidence for informing vaccine guidelines.

Original language	English
Pages (from-to)	217-222
Number of pages	6
Journal	AIDS
Volume	38
Issue number	2
DOIs	https://doi.org/10.1097/QAD.0000000000003751
Publication status	Published - 1 Feb 2024

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Humans
mRNA Vaccines
BNT162 Vaccine
COVID-19 Vaccines
SARS-CoV-2
HIV-1
Cohort Studies
COVID-19/prevention & control
HIV Infections
Antibodies
Antibodies, Viral
Vaccination
Adaptive Clinical Trials as Topic

Access to Document

10.1097/QAD.0000000000003751

Handle.net

Persistent link

Cite this

Swiss HIV Cohort Study, Chammartin, F., Griessbach, A., Kusejko, K., Audigé, A., Epp, S., Stoeckle, M. P., Eichenberger, A. L., Amstutz, A., Schoenenberger, C. M., Hasse, B., Braun, D. L., Rauch, A., Trkola, A., Briel, M., Bucher, H. C., Günthard, H. F., Speich, B., & Abela, I. A. (2024). Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1. AIDS, 38(2), 217-222. https://doi.org/10.1097/QAD.0000000000003751

@article{c77fb876afc347d98adaae7df16d6a16,

title = "Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1",

abstract = "OBJECTIVES: This study aimed to investigate the association of demographic and clinical characteristics, including HIV-specific parameters with the antibody response to a third dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine in people with HIV-1 (PWH).DESIGN: Post hoc analysis of data collected during the observational extension of the COrona VaccinE tRiAL pLatform trial (COVERALL-2) nested into the Swiss HIV Cohort Study (SHCS).METHODS: Serological measurements were conducted on a total of 439 PWH who had received a third dose of either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. Antibody reactivity was assessed using the multifactorial ABCORA immunoassay that defines SARS-CoV-2 seroconversion and predicts neutralization activity. The association between log transformed antibody reactivity and various baseline factors, including vaccine type, demographics, immune and viral status, smoking status, comorbidities, infection history, and co-medication with chemotherapy and immunosuppressive drugs, was investigated using a multivariable linear regression model.RESULTS: Antibody response to third SARS-CoV-2 vaccination was significantly lower among PWH with CD4 + cell count less than 350 cells/μl [ratio of means 0.79; 95\% confidence interval (CI) 0.65-0.95]. Having a detectable HIV-1 viral load at least 50 copies/ml and being on concurrent chemotherapy was associated with an overall lower humoral immune response (ratio of means 0.75; 95\% CI 0.57-1.00 and 0.34; 95\% CI 0.22-0.52, respectively).CONCLUSION: The study highlights the importance of optimal antiretroviral treatment for PWH, emphasizing the need for timely intervention to enhance the vaccine immunogenicity in this population. Moreover, it underscores the significance of sequential mRNA vaccination and provides important evidence for informing vaccine guidelines.",

keywords = "Humans, mRNA Vaccines, BNT162 Vaccine, COVID-19 Vaccines, SARS-CoV-2, HIV-1, Cohort Studies, COVID-19/prevention \& control, HIV Infections, Antibodies, Antibodies, Viral, Vaccination, Adaptive Clinical Trials as Topic",

author = "\{Swiss HIV Cohort Study\} and Fr{\'e}d{\'e}rique Chammartin and Alexandra Griessbach and Katharina Kusejko and Annette Audig{\'e} and Selina Epp and Stoeckle, \{Marcel P\} and Eichenberger, \{Anna L\} and Alain Amstutz and Schoenenberger, \{Christof M\} and Barbara Hasse and Braun, \{Dominique L\} and Andri Rauch and Alexandra Trkola and Matthias Briel and Bucher, \{Heiner C\} and G{\"u}nthard, \{Huldrych F\} and Benjamin Speich and Abela, \{Irene A\}",

year = "2024",

month = feb,

day = "1",

doi = "10.1097/QAD.0000000000003751",

language = "English",

volume = "38",

pages = "217--222",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

Swiss HIV Cohort Study, Chammartin, F, Griessbach, A, Kusejko, K, Audigé, A, Epp, S, Stoeckle, MP, Eichenberger, AL, Amstutz, A, Schoenenberger, CM, Hasse, B, Braun, DL, Rauch, A, Trkola, A, Briel, M, Bucher, HC, Günthard, HF, Speich, B & Abela, IA 2024, 'Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1', AIDS, vol. 38, no. 2, pp. 217-222. https://doi.org/10.1097/QAD.0000000000003751

TY - JOUR

T1 - Bridging the gap

T2 - identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1

AU - Swiss HIV Cohort Study

AU - Chammartin, Frédérique

AU - Griessbach, Alexandra

AU - Kusejko, Katharina

AU - Audigé, Annette

AU - Epp, Selina

AU - Stoeckle, Marcel P

AU - Eichenberger, Anna L

AU - Amstutz, Alain

AU - Schoenenberger, Christof M

AU - Hasse, Barbara

AU - Braun, Dominique L

AU - Rauch, Andri

AU - Trkola, Alexandra

AU - Briel, Matthias

AU - Bucher, Heiner C

AU - Günthard, Huldrych F

AU - Speich, Benjamin

AU - Abela, Irene A

PY - 2024/2/1

Y1 - 2024/2/1

N2 - OBJECTIVES: This study aimed to investigate the association of demographic and clinical characteristics, including HIV-specific parameters with the antibody response to a third dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine in people with HIV-1 (PWH).DESIGN: Post hoc analysis of data collected during the observational extension of the COrona VaccinE tRiAL pLatform trial (COVERALL-2) nested into the Swiss HIV Cohort Study (SHCS).METHODS: Serological measurements were conducted on a total of 439 PWH who had received a third dose of either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. Antibody reactivity was assessed using the multifactorial ABCORA immunoassay that defines SARS-CoV-2 seroconversion and predicts neutralization activity. The association between log transformed antibody reactivity and various baseline factors, including vaccine type, demographics, immune and viral status, smoking status, comorbidities, infection history, and co-medication with chemotherapy and immunosuppressive drugs, was investigated using a multivariable linear regression model.RESULTS: Antibody response to third SARS-CoV-2 vaccination was significantly lower among PWH with CD4 + cell count less than 350 cells/μl [ratio of means 0.79; 95% confidence interval (CI) 0.65-0.95]. Having a detectable HIV-1 viral load at least 50 copies/ml and being on concurrent chemotherapy was associated with an overall lower humoral immune response (ratio of means 0.75; 95% CI 0.57-1.00 and 0.34; 95% CI 0.22-0.52, respectively).CONCLUSION: The study highlights the importance of optimal antiretroviral treatment for PWH, emphasizing the need for timely intervention to enhance the vaccine immunogenicity in this population. Moreover, it underscores the significance of sequential mRNA vaccination and provides important evidence for informing vaccine guidelines.

AB - OBJECTIVES: This study aimed to investigate the association of demographic and clinical characteristics, including HIV-specific parameters with the antibody response to a third dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine in people with HIV-1 (PWH).DESIGN: Post hoc analysis of data collected during the observational extension of the COrona VaccinE tRiAL pLatform trial (COVERALL-2) nested into the Swiss HIV Cohort Study (SHCS).METHODS: Serological measurements were conducted on a total of 439 PWH who had received a third dose of either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. Antibody reactivity was assessed using the multifactorial ABCORA immunoassay that defines SARS-CoV-2 seroconversion and predicts neutralization activity. The association between log transformed antibody reactivity and various baseline factors, including vaccine type, demographics, immune and viral status, smoking status, comorbidities, infection history, and co-medication with chemotherapy and immunosuppressive drugs, was investigated using a multivariable linear regression model.RESULTS: Antibody response to third SARS-CoV-2 vaccination was significantly lower among PWH with CD4 + cell count less than 350 cells/μl [ratio of means 0.79; 95% confidence interval (CI) 0.65-0.95]. Having a detectable HIV-1 viral load at least 50 copies/ml and being on concurrent chemotherapy was associated with an overall lower humoral immune response (ratio of means 0.75; 95% CI 0.57-1.00 and 0.34; 95% CI 0.22-0.52, respectively).CONCLUSION: The study highlights the importance of optimal antiretroviral treatment for PWH, emphasizing the need for timely intervention to enhance the vaccine immunogenicity in this population. Moreover, it underscores the significance of sequential mRNA vaccination and provides important evidence for informing vaccine guidelines.

KW - Humans

KW - mRNA Vaccines

KW - BNT162 Vaccine

KW - COVID-19 Vaccines

KW - SARS-CoV-2

KW - HIV-1

KW - Cohort Studies

KW - COVID-19/prevention & control

KW - HIV Infections

KW - Antibodies

KW - Antibodies, Viral

KW - Vaccination

KW - Adaptive Clinical Trials as Topic

U2 - 10.1097/QAD.0000000000003751

DO - 10.1097/QAD.0000000000003751

M3 - Article (Academic Journal)

C2 - 37830908

SN - 0269-9370

VL - 38

SP - 217

EP - 222

JO - AIDS

JF - AIDS

IS - 2

ER -

Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Handle.net

Fingerprint

Cite this